Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab + GVAX vs FOLFIRINOX in Metastatic Pancreatic Cancer
NCT01896869Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2013
- Primary completion
- May 2019
- Modality
- Cell Therapies, Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, GVAX pancreatic cancer vaccine in pancreatic adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Nov 2013; status: completed.
02
Drugs
ipilimumabGVAX pancreatic cancer vaccine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01896869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01896869.